Fig. 3 | Scientific Reports

Fig. 3

From: JAVEMACS-D: claims database analysis of avelumab maintenance therapy for advanced urothelial carcinoma in Japan

Fig. 3

Outcomes in patients treated with avelumab maintenance. (a) TTF from the start of avelumab maintenance in the overall population. (b) TTF from avelumab maintenance by type of 2L treatment. (c) 2L TTF from the start of 2L treatment by type of 2L treatment. (d) TTF2 from avelumab maintenance by type of 2L treatment. 2L, second line; EV, enfortumab vedotin; PBC, platinum-based chemotherapy,;Pem, pembrolizumab; TTF, time to treatment failure.

Back to article page